Advertisement

Infection

pp 1–4 | Cite as

Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime–avibactam

  • Ibai Los-Arcos
  • Oscar LenEmail author
  • María Teresa Martín-Gómez
  • Juan José González-López
  • Berta Saéz-Giménez
  • María Deu
  • Xavier Nuvials
  • Ricard Ferrer
  • Antonio Román
  • Joan Gavaldà
Brief Report

Abstract

We describe two cystic fibrosis patients infected with pandrug-resistant Burkholderia cepacia complex, with the exception of ceftazidime–avibactam, who received prophylaxis with this antibiotic during lung transplantation. Although both patients had a post-operative relapse of respiratory infection, one with positive blood cultures, ceftazidime–avibactam treatment yielded a favourable outcome. 12 months after transplantation, one patient presented an excellent clinical outcome. However, the other patient died 10 months later due to severe B. cepacia sinusitis with intracranial invasion.

Keywords

Multi-drug resistance Respiratory tract infection Lung transplantation Cystic fibrosis Ceftazidime–avibactam Burkholderia cepacia complex 

Notes

Acknowledgements

Ibai Los-Arcos received a Rio Hortega contract through the 2016 call for Strategic Action in Health from Instituto de Salud Carlos III of the Spanish Health Ministry for the years 2017–2018. The authors thank Celine Cavallo for English language support.

Funding

This research received no specific Grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

I.L. has been a speaker for Pfizer and has received travel support from Gilead, Merck and Novartis. O.L. has received a research grant from Pfizer and has been speaker for Pfizer, Astellas, Novartis and Merck. The rest of the authors declare that they have no conflicts of interest related to this study.

References

  1. 1.
    Abbott IJ, Peleg AY. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies. Semin Respir Crit Care Med. 2015;36:99–110.CrossRefGoogle Scholar
  2. 2.
    Lobo LJ, Noone PG. Respiratory infections in patients with cystic fibrosis undergoing lung transplantation. Lancet Respir Med. 2014;2:73–82.CrossRefGoogle Scholar
  3. 3.
    Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, et al. Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis. 2017;3:502–11.CrossRefGoogle Scholar
  4. 4.
    Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15.CrossRefGoogle Scholar
  5. 5.
    De Soyza A, Meachery G, Hester KLM, Nicholson A, Parry G, Tocewicz K, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Hear lung Transplant. 2010;29:1395–404.CrossRefGoogle Scholar
  6. 6.
    van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase combinations. Clin Infect Dis. 2016;63:234–41.CrossRefGoogle Scholar
  7. 7.
    Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015;46:483–93.CrossRefGoogle Scholar
  8. 8.
    Spilker T, Baldwin A, Bumford A, Dowson CG, Mahenthiralingam E, LiPuma JJ. Expanded multilocus sequence typing for Burkholderia species. J Clin Microbiol. 2009;47:2607–10.CrossRefGoogle Scholar
  9. 9.
    Alexander BD, Petzold EW, Reller LB, Palmer SM, Davis RD, Woods CW, et al. Survival after lung transplantation of cystic Fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant. 2008;8:1025–30.CrossRefGoogle Scholar
  10. 10.
    Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345–52.CrossRefGoogle Scholar
  11. 11.
    Nosotti M, Dell’Amore A, Diso D, Oggionni T, Aliberti S, Study Group for Thoracic Organs Transplantation E, et al. Selection of candidates for lung transplantation: the First Italian Consensus Statement. Transplant Proc. 2017;49:702–6.CrossRefGoogle Scholar
  12. 12.
    Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax. 2008;63:732–7.CrossRefGoogle Scholar
  13. 13.
    Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:363–71.CrossRefGoogle Scholar
  14. 14.
    Hopkins PM, Kidd TJ, Coulter C, Feather IH, Derrington P, Bell SC. Death after lung transplantation in cystic fibrosis patients infected with Burkholderia cepacia. Am J Respir Crit Care Med. 2009;179:257–8.CrossRefGoogle Scholar
  15. 15.
    Torres A, Zhong N, Pachl J, Timsit J-F, Kollef M, Chen Z, et al. Ceftazidime–avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–95.CrossRefGoogle Scholar
  16. 16.
    Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015;70:2862–9.CrossRefGoogle Scholar
  17. 17.
    Tamma PD, Fan Y, Bergman Y, Sick-Samuels AC, Hsu AJ, Timp W, et al. Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime–avibactam. Antimicrob Agents Chemother. 2018;62:e02213-17.CrossRefGoogle Scholar
  18. 18.
    Barlow G, Morice A. Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime/avibactam plus aztreonam. J Antimicrob Chemother. 2018;73:2270–1.CrossRefGoogle Scholar
  19. 19.
    Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime–avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615–8.CrossRefGoogle Scholar
  20. 20.
    Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of ceftazidime–avibactam resistance due to plasmid-borne bla KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61:e02097–16.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Ibai Los-Arcos
    • 1
    • 6
  • Oscar Len
    • 1
    • 6
    Email author
  • María Teresa Martín-Gómez
    • 2
  • Juan José González-López
    • 2
  • Berta Saéz-Giménez
    • 3
  • María Deu
    • 4
  • Xavier Nuvials
    • 5
  • Ricard Ferrer
    • 5
  • Antonio Román
    • 3
  • Joan Gavaldà
    • 1
    • 6
  1. 1.Infectious Diseases DepartmentHospital Universitari Vall d’HebronBarcelonaSpain
  2. 2.Microbiology DepartmentHospital Universitari Vall d’HebronBarcelonaSpain
  3. 3.Lung Transplant UnitHospital Universitari Vall d’HebronBarcelonaSpain
  4. 4.Thoracic Surgery DepartmentHospital Universitari Vall d’HebronBarcelonaSpain
  5. 5.Critical Care DepartmentHospital Universitari Vall d’HebronBarcelonaSpain
  6. 6.Departament of MedicineUniversitat Autònoma de BarcelonaBarcelonaSpain

Personalised recommendations